This JACC analysis examined the time course of cardiovascular and kidney benefits with finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes, characterizing how quickly the cardiorenal protection emerges after treatment initiation.
Publication date: 24 February 2026Source: JACC, Volume 87, Issue 7
